317 related articles for article (PubMed ID: 25227702)
41. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
Greiner J; Döhner H; Schmitt M
Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
[TBL] [Abstract][Full Text] [Related]
42. (Lymph)angiogenic influences on hematopoietic cells in acute myeloid leukemia.
Lee JY; Kim HJ
Exp Mol Med; 2014 Nov; 46(11):e122. PubMed ID: 25412683
[TBL] [Abstract][Full Text] [Related]
43. A Role for Lipid Mediators in Acute Myeloid Leukemia.
Loew A; Köhnke T; Rehbeil E; Pietzner A; Weylandt KH
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31100828
[TBL] [Abstract][Full Text] [Related]
44. [Research Advance on the Immune Escape of Acute Myeloid Leukemia--Review].
Chen HJ; Zhang S; Luo QD; Li J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1429-1432. PubMed ID: 32798439
[TBL] [Abstract][Full Text] [Related]
45. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts.
Gertner-Dardenne J; Castellano R; Mamessier E; Garbit S; Kochbati E; Etienne A; Charbonnier A; Collette Y; Vey N; Olive D
J Immunol; 2012 May; 188(9):4701-8. PubMed ID: 22467661
[TBL] [Abstract][Full Text] [Related]
46. Harnessing the immune system in acute myeloid leukaemia.
Austin R; Smyth MJ; Lane SW
Crit Rev Oncol Hematol; 2016 Jul; 103():62-77. PubMed ID: 27247119
[TBL] [Abstract][Full Text] [Related]
47. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
48. Polymeric nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia cells.
Gul-Uludağ H; Valencia-Serna J; Kucharski C; Marquez-Curtis LA; Jiang X; Larratt L; Janowska-Wieczorek A; Uludağ H
Leuk Res; 2014 Nov; 38(11):1299-308. PubMed ID: 25262448
[TBL] [Abstract][Full Text] [Related]
49. Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis.
Dulphy N; Henry G; Hemon P; Khaznadar Z; Dombret H; Boissel N; Bensussan A; Toubert A
Br J Haematol; 2014 Jun; 165(5):722-5. PubMed ID: 24666252
[No Abstract] [Full Text] [Related]
50. Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.
Knaus HA; Kanakry CG; Luznik L; Gojo I
Curr Drug Targets; 2017; 18(3):315-331. PubMed ID: 25981611
[TBL] [Abstract][Full Text] [Related]
51. Autologous immune strategies to reduce the risk of leukemic relapse: consideration for IL-15.
Blaser BW; Caligiuri MA
Best Pract Res Clin Haematol; 2006; 19(2):281-92. PubMed ID: 16516125
[TBL] [Abstract][Full Text] [Related]
52. Escape from T-cell-targeting immunotherapies in acute myeloid leukemia.
Vadakekolathu J; Rutella S
Blood; 2024 Jun; 143(26):2689-2700. PubMed ID: 37467496
[TBL] [Abstract][Full Text] [Related]
53. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment.
Krönig H; Kremmler L; Haller B; Englert C; Peschel C; Andreesen R; Blank CU
Eur J Haematol; 2014 Mar; 92(3):195-203. PubMed ID: 24175978
[TBL] [Abstract][Full Text] [Related]
54. Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine.
Cheuk AT; Guinn BA
Front Biosci; 2008 Jan; 13():2022-9. PubMed ID: 17981688
[TBL] [Abstract][Full Text] [Related]
55. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.
van Luijn MM; van den Ancker W; Chamuleau ME; Zevenbergen A; Westers TM; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
Cancer Res; 2011 Apr; 71(7):2507-17. PubMed ID: 21310823
[TBL] [Abstract][Full Text] [Related]
56. [Dendritic cell-based therapeutic vaccination for acute myeloid leukemia].
Anguille S; Van Tendeloo V; Berneman Z
Bull Cancer; 2012 Jun; 99(6):635-42. PubMed ID: 22641288
[TBL] [Abstract][Full Text] [Related]
57. Arginase-mediated "field" defects in AML.
Marcucci G
Blood; 2013 Aug; 122(5):620-1. PubMed ID: 23908439
[TBL] [Abstract][Full Text] [Related]
58. [T-cell immunity against autologous leukemic cell mediated by in vitro bone marrow-derived dendritic cell from patients with acute myeloid leukemia in complete remission].
He X; You S; Bian S
Zhonghua Xue Ye Xue Za Zhi; 2001 Dec; 22(12):629-32. PubMed ID: 16200709
[TBL] [Abstract][Full Text] [Related]
59. Recent developments in immunotherapy of acute myeloid leukemia.
Lichtenegger FS; Krupka C; Haubner S; Köhnke T; Subklewe M
J Hematol Oncol; 2017 Jul; 10(1):142. PubMed ID: 28743264
[TBL] [Abstract][Full Text] [Related]
60. Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.
Lin JM; Li B; Rimmer E; VanRoey M; Jooss K
Exp Hematol; 2008 Mar; 36(3):319-28. PubMed ID: 18279719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
